Maruho launches Mitchga, a new antibody drug created by Chugai

Japanese drugmaker Maruho has launched the humanized anti-interleukin (IL)-31 receptor A Mitchga monoclonal antibody (nemolizumab [genetical recombination]) Subcutaneous injection in syringes of 60 mg for the treatment of itching associated with atopic dermatitis (only when the existing treatment is insufficiently effective).

Nemolizumab was licensed to Maruho for the Japanese market in 2016 by Chugai Pharmaceutical (TYO:4519), which is majority owned by…

This article is accessible to registered users, to continue reading, please register for free. A free trial will give you access to exclusive features, interviews, summaries and commentary from the sharpest minds in the pharma and biotech space for one week. If you are already a registered user, please login. If your trial period is over, you can register here.

Try before you buy

• All the news that moves the needle in pharma and biotech.
• Exclusive features, podcasts, interviews, data analysis and commentary from our global network of life science journalists.
• Receive The Pharma Letter daily newsletter, free forever.

Become a subscriber

• Unfettered access to top pharmaceutical and biotechnology industry news, commentary and analysis.
• Updates on clinical trials, conferences, mergers and acquisitions, licensing, financing, regulatory, patent and legal, executive appointments, business strategy and financial results.
• Daily roundup of key events in pharma and biotechnology.
• In-depth monthly briefings on board appointments and M&A news.
• Choose between an economical annual plan or a flexible monthly subscription.

Comments are closed.